Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy

We aimed to investigate the prognostic value of the relative maximum standardized uptake value (SUV) of metastatic lymph node (LN) compared with that of primary tumor (SUV / SUV ) based on a pretreatment [ F]-FDG PET/CT scan in patients with clinically node-positive esophageal squamous cell carcinom...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2020-03, Vol.12 (3), p.607
Main Authors: Lin, Chia-Hsin, Hung, Tsung-Min, Chang, Yu-Chuan, Hsieh, Chia-Hsun, Shih, Ming-Chieh, Huang, Shih-Ming, Yang, Chan-Keng, Chang, Ching-Fu, Chan, Sheng-Chieh, Yap, Wing-Keen
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to investigate the prognostic value of the relative maximum standardized uptake value (SUV) of metastatic lymph node (LN) compared with that of primary tumor (SUV / SUV ) based on a pretreatment [ F]-FDG PET/CT scan in patients with clinically node-positive esophageal squamous cell carcinoma (cN+ ESCC) treated with definitive chemoradiotherapy (dCRT). We retrospectively evaluated cN+ ESCC patients who underwent a PET/CT scan before dCRT. Time-dependent receiver operating characteristics analysis was performed to identify the optimal cutoff value for SUV / SUV . Prognostic influences of SUV / SUV on distant metastasis-free survival (DMFS) and overall survival (OS) were evaluated using the Kaplan-Meier method and log-rank test for univariate analysis and Cox's proportional hazards regression model for multivariate analysis. We identified 112 patients with newly diagnosed cN+ ESCC. After a median follow-up of 32.0 months, 50 (44.6%) patients had distant failure and 84 (75.0%) patients died. Patients with high SUV / SUV (≥ 0.39) experienced worse outcomes than low SUV / SUV (< 0.39) (two-year DMFS: 26% vs. 70%, p < 0.001; two-year OS: 21% vs. 48%, p = 0.001). Multivariate analysis showed that SUV / SUV was an independent prognostic factor for both DMFS (adjusted HR 2.24, 95% CI 1.34-3.75, = 0.002) and OS (adjusted HR 1.61, 95% CI 1.03-2.53, = 0.037). Pretreatment of SUV / SUV is a simple and useful marker for prognosticating DMFS and OS in cN+ ESCC patients treated with dCRT, which may help in tailoring treatment and designing future clinical trials.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12030607